Bayer drug could ease side effects of common breast cancer treatment, detailed data show

Bayer drug could ease side effects of common breast cancer treatment, detailed data show

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer application for approval.

Bayer's Elinzanetant Shows Promise in Mitigating Breast Cancer Treatment Side Effects

Bayer’s investigational drug, elinzanetant, offers new hope for women undergoing endocrine therapy for breast cancer by effectively managing vasomotor symptoms such as hot flashes and disrupted sleep. The Oasis-4 trial, a late-stage clinical study, demonstrated the drug’s potential in reducing these menopausal-like side effects, which affect nearly 90% of women treated with endocrine drugs for hormone receptor-positive breast cancer. Vasomotor s…